I think your logic is flawed. The latest quarterly simply confirms what I am saying.
a) No organic revenue growth of note. All acquisition based.
b) Average of 400 patients per pharmacy per year! Given the average pharmacy does 4000 scripts a month, or 48,000 a year, MedAdvisor is hardly making a meaningful dent in pharmacies revenues. See point c) below.
c) $140m in script orders over the entire base PA equates to $51k per year per pharmacy! that is nothing!
d) Revenue increased (due to acquisitions) to $7.2m (51%), and loss increases 30%. Can't get excited by that.
e) And despite the failure to prove the model in Australia, they are now trying it offshore.
What is it that I am missing here? I would be very happy to be corrected with my understanding of the facts. As I have said, I like the idea. I think the app is ok. But something is going terribly wrong with adoption rates.
- Forums
- ASX - By Stock
- Medadvisor stearing patients away from smaller pharmacies?
I think your logic is flawed. The latest quarterly simply...
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $215.0M |
Open | High | Low | Value | Volume |
29.0¢ | 29.5¢ | 27.5¢ | $248.7K | 869.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 24636 | 27.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 13888 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15939 | 0.335 |
3 | 26030 | 0.330 |
1 | 100000 | 0.325 |
4 | 89161 | 0.320 |
2 | 29526 | 0.315 |
Price($) | Vol. | No. |
---|---|---|
0.360 | 24455 | 1 |
0.380 | 50000 | 1 |
0.385 | 100000 | 1 |
0.390 | 54500 | 1 |
0.395 | 10000 | 1 |
Last trade - 15.28pm 15/11/2024 (20 minute delay) ? |
MDR (ASX) Chart |